Advertisement Court approves delay in Plavix patent infringement suit - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Court approves delay in Plavix patent infringement suit

The pre-trial order on Plavix, a top selling blood thinner, has been put back at the request of all parties; Apotex, Dr Reddy's Laboratories and Sanofi-Aventis. The patent-infringement litigation is now due to take place on May 27, 2005.

The patent infringement suit surrounding Sanofi-Aventis’s Plavix, the world’s third largest selling medication, was previously scheduled for May 13, 2005. Canadian company Apotex and India’s Dr Reddy’s Laboratories, have been challenging the patent since 2002 in the hope of selling cheaper versions of Plavix in the US.

Following what is now the fourth delay of the pre-trial order, analysts have forecast a year long trial.

Although the litigation has the potential to open up the US market, it should be noted that Sanofi successfully defended Plavix’s Canadian patent against an attack by Apotex earlier this year.